Survey of Oncology Nurses Reveals Knowledge Gaps Regarding PARP Inhibitor Therapies

Poly(ADP)-ribose polymerase (PARP) inhibition is a new form of targeted therapy that has exhibited effectiveness in treating several solid tumor types. Olaparib (Lynparza®, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula®, Tesaro) have all been approved for the treatment of advanced ovarian cancer. Olaparib has also been approved to treat BRCA-mutated breast cancer and is currently being investigated in the treatment of prostate cancer. Another PARP inhibitor, talazopa...
Continue reading

PARP Inhibitor Effective in Advanced Pancreatic Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors, such as rucaparib (Rubraca®, Clovis Oncology), have been shown to be effective for cancers containing BRCA mutations. They have also been successful as maintenance therapy for platinum-sensitive ovarian cancer treated with PARP inhibitors. Therefore, researchers conducted a phase 2 clinical trial to determine if patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic BRCA or PALB2 mutation whose cancer had n...
Continue reading

Ovarian Cancer: Researchers Predict PARP Inhibitor Response

​ Researchers have found a way to identify which patients with high-grade serous ovarian carcinoma (HGSOC), the most malignant and most common form of ovarian cancer, will respond to poly (ADP-ribose) polymerase (PARP) inhibitor therapy. The answer to this question, as addressed in a study published in Nature Communications , could allow doctors to tailor patients' therapy on an individual basis, facilitating better treatment responses and increased chances of survival. Mutations of two BRCA gen...
Continue reading

FDA Grants Approval to Rucaparib for Maintenance in Recurrent Ovarian Cancer

Rucaparib (Rubraca, Clovis Oncology Inc.) has received FDA approval for use as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Approval was based on the phase III ARIEL3 trial, which was comprised of an intent-to-treat population of 564 patients. Results from the trial showed a progression-free survival of 10.8 months with rucaparib compared with 5.4 months w...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.